Ribociclib

Mechanism of Action

Ribociclib is a cancer medication that works by inhibiting the activity of specific enzymes called cyclin-dependent kinases (CDKs) 4 and 6. These enzymes play a critical role in the regulation of cell division, and their overactivity is commonly associated with the development of certain types of cancer, particularly breast cancer.

By blocking the activity of CDK4/6, ribociclib slows down the uncontrolled cell division that drives the growth of cancer cells. This helps to reduce the size of tumors and slows down the progression of the disease.

Ribociclib is typically used in combination with other cancer treatments, such as hormone therapy, to help improve the overall effectiveness of treatment. The drug is approved for the treatment of hormone receptor-positive, HER2-negative advanced or metastatic breast cancer in combination with an aromatase inhibitor.

Indication

Ribociclib is a medication used for the treatment of certain types of breast cancer. It is specifically indicated for the treatment of hormone receptor-positive, HER2-negative advanced or metastatic breast cancer in combination with an aromatase inhibitor.

This type of breast cancer is characterized by the presence of certain hormones (estrogen and/or progesterone) that help to fuel the growth of the cancer cells. Ribociclib is used to target these hormones and slow down the progression of the disease.

In clinical trials, ribociclib has been shown to significantly improve progression-free survival (the length of time during which a patient's cancer does not worsen) compared to treatment with an aromatase inhibitor alone. This makes it an important option for women with advanced or metastatic breast cancer who are seeking to extend the time until their cancer progresses.

Dr. Reddy's Expertise

Headquartered in Hyderabad, India, Dr. Reddy's Laboratories is one of the leading Active Pharmaceutical Ingredients (API) manufacturers and suppliers globally for Ribociclib API. Dr. Reddy's API business is a preferred partner to pharma companies across the US, Europe, Brazil, Latin America, Japan, China, Korea, Middle East and other emerging markets.

Dr. Reddy's API business thrives on the deep technical strengths established over the last 30+ years in the development and manufacture of complex APIs such as steroids, peptides, complex long chain molecules and highly potent APIs (HPAPIs / oncology drugs). This expertise is complemented by our prowess in intellectual property and regulatory affairs which helps us consistently meet and exceed regulatory standards. Dr. Reddy's Ribociclib API is the outcome of the extensive expertise in R&D, IP, and Regulatory.

A key component in helping our customers be first to market is a responsive supply chain. We achieve this by making sure that all our facilities are operating efficiently and to the latest standards of quality, safety, and productivity. A strong interconnect between business and factories allows for a quick reaction to dynamic market changes, so that we can avert shortages and meet sudden surges in demand.